A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.

• Main Authors: Alison Krentel (Author), Nandha Basker (Author), Madsen Beau de Rochars (Author), Joshua Bogus (Author), Daniel Dilliott (Author), Abdel N Direny (Author), Christine Dubray (Author), Peter U Fischer (Author), Adriani Lomi Ga (Author), Charles W Goss (Author), Myra Hardy (Author), Cade Howard (Author), Purushothaman Jambulingam (Author), Christopher L King (Author), Moses Laman (Author), Jean Frantz Lemoine (Author), Shruti Mallya (Author), Leanne J Robinson (Author), Josaia Samuela (Author), Ken B Schechtman (Author), Andrew C Steer (Author), Taniawati Supali (Author), Livingstone Tavul (Author), Gary J Weil (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<h4>Background</h4>Many countries will not reach elimination targets for lymphatic filariasis in 2020 using the two-drug treatment regimen (diethylcarbamazine citrate [DEC] and albendazole [DA]). A cluster-randomized, community-based safety study performed in Fiji, Haiti, India, Indonesi...